Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA003624 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA003624, RRID:AB_10602123
- Product name
- Anti-RBM3
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human RBM3, Gene description: RNA binding motif (RNP1, RRM) protein 3, Alternative Gene Names: IS1-RNPL, Validated applications: WB, IHC, ICC, Uniprot ID: P98179, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Characterization of RNA‐binding motif 3 (RBM3) protein levels and nuclear architecture changes in aggressive and recurrent prostate cancer
High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer
Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome
High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer
Generation of monospecific antibodies based on affinity capture of polyclonal antibodies
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer
Carleton N, Zhu G, Miller M, Davis C, Kulkarni P, Veltri R
Cancer Reports 2020;3(3)
Cancer Reports 2020;3(3)
High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer
Kang S, Cho J, Jeong H, Kwon S
Journal of Breast Cancer 2018;21(3):288
Journal of Breast Cancer 2018;21(3):288
Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome
Grupp K, Hofmann B, Kutup A, Bachmann K, Bogoevski D, Melling N, Uzunoglu F, El Gammal A, Koop C, Simon R, Steurer S, Krech T, Burdak-Rothkamm S, Jacobsen F, Sauter G, Izbicki J, Wilczak W
BMC Cancer 2018;18(1)
BMC Cancer 2018;18(1)
High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer
Hjelm B, Brennan D, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Pontén F, Johannesson H, Smaragdi K, Frantz C, Hober S, Johnson L, Påhlman S, Jirström K, Uhlen M
PROTEOMICS – Clinical Applications 2011;5(11-12):624-635
PROTEOMICS – Clinical Applications 2011;5(11-12):624-635
Generation of monospecific antibodies based on affinity capture of polyclonal antibodies
Hjelm B, Forsström B, Igel U, Johannesson H, Stadler C, Lundberg E, Ponten F, Sjöberg A, Rockberg J, Schwenk J, Nilsson P, Johansson C, Uhlén M
Protein Science 2011;20(11):1824-1835
Protein Science 2011;20(11):1824-1835
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer
Jögi A, Brennan D, Rydén L, Magnusson K, Fernö M, Stål O, Borgquist S, Uhlen M, Landberg G, Påhlman S, Pontén F, Jirström K
Modern Pathology 2009;22(12):1564-1574
Modern Pathology 2009;22(12):1564-1574
No comments: Submit comment
Enhanced validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Genetic validation
- Main image
- Experimental details
- Western blot analysis in U-251MG cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-RBM3 antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.
- Sample type
- Human
- Protocol
- Protocol
